The COVID-19 pandemic continues to dominate the news and is likely to for quite some time. The biopharma industry is doing what it can to test and repurpose therapies, develop diagnostics and respond to the crisis. Also, although some clinical trials are being slowed...
Farxiga is the first SGLT2 inhibitor to show meaningful benefit in patients with chronic kidney disease in a trial including both type-2 diabetics and non-diabetics The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III...
Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation of pulmonary function (HOPE)) SEATTLE, March 30, 2020...
PARIS and TARRYTOWN, N.Y. – March 30, 2020 – The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19. The global clinical program has now been initiated...
The Covid-19 pandemic has shined a bright light on the need to manage patients remotely wherever possible. This need is especially acute in clinical trials as identified by the FDA. Trial sponsors, physicians and regulators are now embracing the use of technology to...
SUZHOU, China, and ROCKVILLE, Md., March 23, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today...
Email
Text